Brentuximab as First Salvage Therapy in Hodgkin's Lymphoma

February 19, 2015

In patients with relapsed or refractory Hodgkin's lymphoma, brentuximab vedotin (Adcetris, Seattle Genetics) might be an effective first salvage therapy.

The product, a novel agent that targets CD30, is currently approved for use in patients with Hodgkin's lymphoma after the failure of autologous stem cell transplantation (ASCT) or the failure of at least two multiagent chemotherapy regimens in patients not candidates for ASCT.

Read the full story.